01 Enterprise Adoption of Digital Pathology Workflows The cellular pathology market analysis shows a clear shift from microscope-led review toward enterprise digital pathology workflows that connect slide scanning, image management, and remote diagnostic review. This improves case access and laboratory throughput. For example, Proscia reported that its Concentriq platform was on track to support 32,000 patient diagnoses daily, representing a 400% year-over-year increase in daily cases.
02 AI-Assisted Tissue Biomarker Interpretation Cellular pathology laboratories are increasingly adopting AI-assisted interpretation for immunohistochemistry and tissue-based biomarker assessment. These tools support more consistent scoring and help pathologists manage complex oncology cases without replacing clinical review. T
01 Supply chain disruptions are expected to have a moderate impact on the cellular pathology market share due to the sector’s dependence on specialized reagents, antibodies, laboratory consumables, and instrument components. Large diagnostic companies can manage disruptions more effectively through established supplier networks. Smaller laboratories may face procurement delays and higher costs. The market is expected to grow at a CAGR of 7.90%, but supply chain constraints could temporarily reduce growth by around 1.2 percentage points to 6.70%.
01 The cellular pathology market forecasts investment in digital pathology platforms, AI-based image analysis, and integrated diagnostic workflows. In April 2026, Techcyte raised USD 15 million in capital led by Van Tuyl Companies, with participation from Mayo Clinic and Zoetis. The funding supports growth of its AI-powered pathology diagnostic solutions.
01 Tissue-Based Cancer Diagnostic and Expansion of Predictive Tissue Biomarker Testing Drives Market Cellular pathology demand is rising as more patients require tissue confirmation, tumor classification, grading, and biomarker assessment before treatment. The WHO’s 2026 cancer status report estimates 20.6 million new cancer cases annually and projects nearly 35 million by 2050. As most solid tumors still depend on histology or cytology for definitive diagnosis, the growing case load directly increases slide preparation, staining, imaging, and pathologist review volumes across laboratories.The shift from diagnosis-only pathology to treatment-guided tissue analysis is increasing the number of tests performed on each cancer specimen. Current ASCO guidance recommends PD-L1, HER2, MMR/MSI, and CLDN18.2 testing in gastroesophageal adenocarcinoma. The same guidance notes PD-L1 positivity around 79% and CLDN18.2 expression in almost 40% of patients. This broader biomarker workload supports demand for immunohistochemistry, in situ hybridization, digital interpretation, and higher-throughput cellular pathology systems.
01 Shortage of Trained Pathologists and Pre-analytical Variability Restrain Market Expansion Shortages of trained histology and anatomic pathology professionals restrict laboratory capacity and slow diagnostic workflows. Limited staffing increases case backlogs, extends turnaround times, and places pressure on existing personnel. Persistent workforce gaps also make it difficult for laboratories to expand testing volumes, maintain consistent quality, and implement more complex pathology procedures.Cellular pathology results remain highly dependent on specimen handling, fixation, staining quality, and assay-specific interpretation. Small biopsies and cytology samples can provide limited material, while alternative fixatives may change immunohistochemical sensitivity. CAP guidance requires separate validation for certain fixatives and distinct predictive-marker scoring systems. These requirements increase validation workload, quality-control costs, and repeat-testing risk.
01 Spatial Biology & High-Plex Tissue Imaging and Non-destructive 3D Tissue Imaging Open New Avenues for Market Players Spatial biology creates a new opportunity to move cellular pathology beyond single marker staining toward high-content tissue characterization. Modern multiplex protein imaging can routinely visualize about 40 to 50 markers in the same tissue section at single-cell or subcellular resolution. The integration of these images with spatial transcriptomics can map tumor cells, immune cells, and their interactions while preserving tissue architecture. This can expand pathology services into advanced tumor profiling, translational diagnostics, and therapy-response assessment. Non-destructive 3D tissue imaging creates a new opportunity for cellular pathology by examining intact specimens without repeated physical sectioning. Tissue clearing combined with light sheet microscopy preserves volumetric architecture and can reveal tumor boundaries, invasion pathways, and small lesions that may be missed in two-dimensional sections.